Dr. Hey works on ethical, policy, and methodological issues at the intersection of philosophy of science and biomedical research ethics. He has published on a variety of topics, including the ethics of placebo-controlled trials, adaptive randomization, risk minimization in early-phase human trials, discordant evidence, complexity and coordination problems in cancer biomarker research, and why clinical investigators ought to make explicit likelihood predictions in their research protocols. He has also developed a graph-theoretic approach to representing medical research programs. Published examples of the approach thus far have included research programs in tuberculosis and diagnostic development in precision medicine, but more examples--particularly in cancer drug development--will be appearing in print soon.
Dr. Hey received his Ph.D. in philosophy from the University of Western Ontario and a B.A. in philosophy from the University of Illinois at Chicago. He is currently a faculty member at the Harvard Center for Bioethics and a research fellow in the Department of Medicine and the Division of Pharmacoepidemiology & Pharmacoeconomics at the Brigham and Women's Hospital. He previously held a research fellowship in the Biomedical Ethics Unit at McGill University and a visiting scholarship at the University of Oxford.
BMJ (Clinical research ed.), January 25, 2018
BMJ (Clinical research ed.), December 28, 2017
Clinical pharmacology and therapeutics, September 25, 2017
Science (New York, N.Y.), September 1, 2017
Circulation. Cardiovascular quality and outcomes, June 1, 2017
The Hastings Center report, March 1, 2017
Journal of Medical Ethics, February 6, 2017
The oncologist, October 24, 2016
BMJ (Clinical research ed.), August 15, 2016
Science (New York, N.Y.), July 29, 2016
Clinical trial participants should have a say in new drug pricingBy Spencer Phillips HeyStat News. May 18, 2017